Co-Diagnostics Inc (CODX)
NASDAQ:CODX
Want to see CODX full AI Analyst Report?
CODX Stock Chart & Stats
$0.26
-$0.07(-8.42%)
At close: 4:00 PM EST
$0.26
-$0.07(-8.42%)
Day’s Range― - ―
52-Week Range$1.26 - $46.50
Previous CloseN/A
Volume146.43K
Average Volume (3M)10.09M
Market Cap
$15.81M
Enterprise Value$3.32M
Total Cash (Recent Filing)$8.23M
Total Debt (Recent Filing)$2.03M
Price to Earnings (P/E)―
Beta2.49
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.26
Shares Outstanding3,685,314
10 Day Avg. Volume1,334,715
30 Day Avg. Volume10,088,102
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market Cap0.21
Enterprise Value/Revenue4.62
Enterprise Value/Gross Profit48.72
Enterprise Value/Ebitda-0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-12.15
Revenue Forecast (FY)$552.40K
Bulls Say, Bears Say
Bulls Say
International Commercial ExpansionPlanned joint ventures and international expansion targeting tuberculosis and HPV markets may open significant new revenue streams and expand commercial footprint.
Point-of-care PerformancePCR Pro's laboratory-grade diagnostic performance in a compact, low-cost device supports adoption in decentralized clinics and other point-of-care settings.
Technology PotentialAnalyst maintains that the company's Co‑Primer technology could differentiate the platform by enabling more specific and reliable nucleic acid detection.
Bears Say
Capital Access ConstraintsPotential delisting could impede access to capital markets, raising the likelihood of funding constraints that would hinder operations and growth plans.
Exchange Delisting RiskRisk of delisting from a major exchange prompted analysts to assign Hold ratings, reflecting increased marketability concerns for the shares.
Regulatory And Listing UncertaintyOngoing listing and regulatory uncertainty is undermining investor confidence and may suppress the stock's valuation despite product strengths.
Co-Diagnostics News
CODX FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was $1.26 and its highest was $46.50 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is $15.81M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on May 14, 2026. The company reported -$4.06 earnings per share for the quarter, missing the consensus estimate of N/A by -$4.06.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Overvalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 3,685,314 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -$4.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -21.166%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in CODX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company that designs, produces, and globally markets specialized reagents. These components are integral to diagnostic tests that identify and analyze nucleic acid molecules. The company's product portfolio features the Co-Dx PCR platform, enabling Polymerase Chain Reaction (PCR) testing for patients in both clinical (point-of-care) and home settings. They offer an extensive range of PCR diagnostic tests for numerous conditions, including COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. Beyond human health, Co-Diagnostics develops three distinct multiplexed tests for screening mosquitos to detect disease-carrying pathogens. Their advanced molecular tools also serve broader applications, encompassing infectious disease detection, liquid biopsy for cancer screening, and agricultural uses such as identifying genetic traits in plant and animal genomes. Complementing these offerings is a portable diagnostic device, specifically engineered to make PCR testing accessible directly to patients in various settings. The company was founded in 2013 and is based in Salt Lake City, Utah.
CODX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful operational and regulatory progress across multiple strategic fronts — completed upper respiratory enrollment (>1,400 patients), India manufacturing license and expanded TAM (~$13B), TB clinical start timing, land allocation in Saudi Arabia, and manufacturing automation plans (~4x efficiency). However, the company still reports very limited absolute revenue, a negative gross margin, widening net loss and adjusted EBITDA losses, and a substantial cash decline to $8.2M with an anticipated need for additional capital. Program-level uncertainties (COVID prevalence affecting submission scope), unfinished manufacturing rollouts and no assurance on strategic transactions temper the positive operational milestones. Overall, operational momentum is clear, but financial constraints and execution risks balance the outlook.View all CODX earnings summariesTechnical Analysis
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Ownership Overview
8.71% Insiders
0.98% Mutual Funds
1.12% Other Institutional Investors
89.19% Public Companies and
Individual Investors